The product is used to treat patients with small cell lung or ovarian cancer who failed initial therapy.
The firm stated that the cohort expansion comes after the initial stage of the trial confirmed that the maximum tolerated dose of ME-344 in combination with topotecan is 10mg/kg, the same dose defined for single agent use. As part of the cohort-expansion stage, the trial is to enroll an additional 40 patients into two cohorts, locally advanced or metastatic small cell lung cancer and ovarian cancer. The Phase Ib trial is intended to evaluate the combination of intravenous ME-344 and topotecan (Hycamtin).
Perrigo to acquire United States rights for Entocort from AstraZeneca
US FDA approves Boehringer Ingelheim's Pradaxa
Phase II clinical trial for potential treatment of androgenetic alopecia completed by Samumed
Life Sciences Partners collaborates on immuno-oncology with Bristol-Myers Squibb
Arsanis initiates first cohort in Phase one clinical trial of ASN100
Impax introduces generic Avodart (Dutasteride) Capsules, 0.5 mg
Mylan unveils generic FazaClo orally disintegrating tablets for treating schizophrenia